Q-omics provides the consensus-scored MAK profile across patient tissues and cancer cell-line models. MAK expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MAK is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, MAK RNA expression shows 20,965 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, LUSC, and THYM as cancer lineages where MAK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAK survival associations across molecular data types. MAK RNA expression shows survival associations in the most cancer types (29), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAK RNA expression–survival associations across cancer types. High MAK expression shows unfavorable associations in KICH and KIRC, but favorable associations in HNSC, READ, UCS and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MAK RNA expression.
This table summarizes MAK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MAK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAK shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in STAD, COAD and CHOL. The LUSC box plot shows higher MAK RNA expression in normal versus tumor tissue (log2 FC = −1.308, t-test p < 0.001).
This table shows molecular features associated with MAK in patient tissues and cancer cell lines. In patient samples, MAK shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
